News und Analysen
Merck: 4 No-Brainer Reasons to Buy This Dip
Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the market can be unforgiving when companies even slightly miss
Fresenius SE Stock: Shares Rally Near 52-Week High
Fresenius SE demonstrated remarkable momentum on the Frankfurt Stock Exchange today, with shares climbing 1.1 percent to reach €37.07. The stock, which opened at €36.50, achieved an intraday peak of
EQS-News: Aufsichtsrat der Sartorius AG schlägt Dividende in Höhe von 0,74 Euro je Vorzugsaktie vor
Fresenius SE Stock: Accelerates Exit from Vamed Projects
Fresenius SE, the German healthcare giant, is expediting its strategic realignment through a swift divestment of Vamed's international project operations. The DAX-listed company has announced the
EQS-News: Sartorius schließt Geschäftsjahr 2024 mit sehr gutem 4. Quartal und positivem Trend ab; Gesamtjahresprognose erreicht
2 Pharmaceutical Stocks to Buy at a Discount
If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump
After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, thanks to several positive developments. The stock has increased by 20%
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than
Is This Pharmaceutical Giant a Buy After a Major Acquisition?
Are things finally looking up for Merck (NYSE: MRK)? After being mostly southbound for the better part of the last two years, the pharmaceutical giant is showing signs of life. Over the past month
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?
Over the past 18 months, Merck (NYSE: MRK) shares have been mostly southbound as the drugmaker encountered several headwinds. Its vaccine business isn't performing as well as expected, resulting in
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price. Even worse, the pharmaceutical giant could face more issues ahead
1 Incredible Reason to Buy LLY's Stock in November
Drug giant Eli Lilly (NYSE: LLY) now has the best-selling drug on the planet. It's a GLP-1 dual receptor agonist called tirzepatide, which Lilly sells as Mounjaro for treating type 2 diabetes and
2 Stocks Down 13% and 34% to Buy Right Now
All things considered, broader equities have performed pretty well in 2025, with the S&P 500 up 14% since the beginning of the year. It seems so long ago that the index flirted with bear-market
This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?
Eli Lilly (NYSE: LLY) manufactures a drug called tirzepatide, a GLP-1 dual receptor agonist, which it sells as Mounjaro for treating type 2 diabetes and Zepbound for weight loss. Tirzepatide became
Why Merck Is Sinking This Week
The stock for pharmaceutical giant Merck (NYSE: MRK) was trading down more than 3% Monday morning. That's a big drop in just a few hours to start the week.
So, what's going on?
It might have to do
3 Healthcare Stocks to Buy Hand Over Fist in October
If you are looking for a healthcare stock to add to your portfolio as October draws to a close, consider Intuitive Surgical (NASDAQ: ISRG), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Each
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means
EQS-News: Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%. Compared to that, Merck's (NYSE: MRK) roughly 4% yield is highly attractive. And LTC Properties' (NYSE:
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge
3 High-Yielding Dividend Stocks That Are Trading Near Their 52-Week Lows
The S&P 500 (SNPINDEX: ^GSPC) is offering investors a tiny yield of just 1.2% today. If you think you are being starved of dividend income, well, that's because you are. But you can do much better
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States